TABLE 1.

Baseline Patient Characteristics (N = 5)

Age (yrs)	79 (69.5–88)
Female	3 (60)
BSA (m2)	1.8 (1.6–2.1)
Comorbidities
Severe COPD	0
Diabetes	1 (20)
Coronary artery disease	1 (20)
Prior coronary artery bypass grafting	0
Prior aortic valve replacement	2 (40)
NYHA functional class III or IV	5 (100)
≥2 cardiac surgical procedures	2 (40)
STS Predicted Risk of Mortality	7.0 (4.0–8.4)
MitraClip setting
Primary MR	2
Secondary MR	1
Mixed MR	1
Unknown	1
Time from MitraClip placement (yrs)	2 (1.3–3.5)
Baseline hemoglobin (mg/dl)	12.8 (10.95–13.6)
Glomerular filtration rate (ml/min/1.73 m2)	54 (31–67.5)
Medications
ACE inhibitor, ARB, or vasodilator	3 (60)
Beta-receptor antagonist	3 (60)
Aspirin or antiplatelet agent	4 (80)
Transthoracic echocardiographic parameters
Left ventricular ejection fraction %	55 (45–55)
Baseline mean mitral valve gradient (mm Hg)	4.5 (4.0–5.0)
Grade III or IV MR severity	5 (100)
Right ventricular dysfunction
Normal	3 (60)
Mild	1 (20)
Moderate	1 (20)
Severe	0
Severe tricuspid regurgitation	1 (20)

Values are median (interquartile range), n (%), or n.

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BSA = body surface area; COPD = chronic obstructive pulmonary disease; MR = mitral regurgitation; NYHA = New York Heart Association; STS = Society of Thoracic Surgeons.